Therapeutic Advances in Medical Oncology
Share

Therapeutic Advances in Medical Oncology

2014 Impact Factor: 2.827
2014 Ranking: 106/211 in Oncology
Source: 2014 Journal Citation Reports ® (Thomson Reuters, 2015)

Editor
Gordon Mallarkey SAGE Publications Ltd, UK
Associate Editors
Tanya B. Dorff USC Keck School of Medicine, Los Angeles, CA, USA
Axel Grothey Mayo Clinic, Rochester, MN, USA
Sara A. Hurvitz University of California, USA
Jonathan Ledermann UCL Cancer Institute, London, UK
Karl Lewis University of Colorado, USA
Frances A Shepherd Princess Margaret Hospital, Toronto, ON, Canada

eISSN: 17588359| ISSN: 17588340|Current volume: 7|Current issue: 2 Frequency: Bi-monthly

Therapeutic Advances in Medical Oncology delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of cancer.
The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in medical oncology, providing a forum in print and online for publishing the highest quality articles in this area. The editors welcome articles of current interest on research across all areas of oncology, including chemotherapy, endocrine therapy, biological therapy and immunotherapy, as well as adjuvant systemic therapy. All cancers are covered including gynaecological cancers, lung cancer, gastrointestinal cancers, urological cancers, head and neck cancers, and skin cancer.

It publishes expert opinion reviews (including single-drug and drug class reviews), narrative reviews and analysis of published guidelines (as editorials or reviews). Original research manuscripts of well-designed trials are also welcomed that show drug or drug class efficacy in a particular disease or therapeutic area. The journal strongly encourages the submission of original research with positive or negative results.

The journal adheres to a blind review process in which the reviewer's name is routinely withheld from the author unless the reviewer requests a preference for their identity to be revealed. Manuscripts are reviewed by at least two referees - a first editorial decision is generally reached within 3 weeks of submission. Online publication of articles occurs within 7 weeks from acceptance. Further information for contributors is provided on the back pages of each issue and online.

For all commercial sales and sponsorship enquiries, including advertising, reprints and supplements, please contact:

Commercial Sales Team, London, UK
Tel. +44 20 7336 1205
Email. reprints@sagepub.co.uk

This journal is a member of the Committee on Publication Ethics (COPE).

The Journal is aimed at researchers and clinicians involved in the medical treatment of cancer and is a forum for publishing original research and reviews in this area. It covers systemic cancer treatments including chemotherapy, endocrine therapy, biological therapy and immunotherapy, as well as adjuvant systemic therapy. All cancers are covered including gynaecological cancers, lung cancer, gastrointestinal cancers, urological cancers, head and neck cancers, and skin cancer.

Therapeutic Advances in Medical Oncology adheres to a blinded peer review process in which the reviewer's name is routinely withheld from the author unless the reviewer requests a preference for their identity to be revealed.

Rapid Peer Review Process: Each research article and review manuscript is reviewed by at least two referees. All manuscripts are reviewed as rapidly as possible, and a first editorial decision is generally reached within 3 weeks of submission.

1. The purpose of the Journal is to publish (in the English language) articles, reviews and scholarly comment (judged worthy of publication by appropriate specialists and accepted by the Editor) relating to medical oncology. The Journal is for all professionals and is a forum for all views on related subjects. The editorial board welcomes articles of current interest on original research, reviews and clinical studies.

2. The Journal will be international in the sense that it will seek, wherever possible, to publish material from authors with an international reputation and articles that are of interest to an international audience.

3. In pursuit of the above the journal shall:

(i) draw on and include high quality work from the international community of scholars including those in the major countries of Europe, Australasia, the United States, other parts of the Americas, countries in the Third World and elsewhere with due representation for considerations of the readership. The Journal shall include work representing the major areas of interest in contemporary research in medical oncology.

(ii) avoid bias in favour of the interests of particular schools or directions of research or particular political or narrow disciplinary objectives to the exclusion of others;

(iii) ensure that articles are written in a terminology and style which makes them intelligible, not merely within the context of a particular discipline or abstract mode, but across the domain of relevant disciplines.

Editorial Board
Dr. Dirk Arnold Tumor Biology Center, Freiburg, Germany
Carlos L Arteaga Vanderbilt University, Nashville, TN, USA
Christopher Benz Buck Institute for Age Research, Novato, CA, USA
Michael Boyer University of Sydney, Sydney, Australia
Kim N Chi University of British Columbia, Vancouver, BC, Canada
Toni K Choueiri Dana-Farber Cancer Institute, Boston, MA, USA
Ronald de Wit Erasmus University Rotterdam, Rotterdam, The Netherlands
Wilfried Eberhardt University Duisburg-Essen, Essen, Germany
Tim Eisen Cambridge University, Cambridge, UK
Alfredo Falcone University of Pisa, Livorno, Italy
Michael Findlay University of Auckland, Auckland, New Zealand
Jorge A. Garcia Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA
Cesare Gridelli S.G. Moscati Hospital, Avellino, Italy
Nasser H. Hanna Indiana University - Purdue University, Indianapolis, IN, USA
Paul R Helft Indiana University School of Medicine, Indianapolis, IN, USA
Maha Hussain University of Michigan, Ann Arbour, MI, USA
David H Ilson Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Sung-Bae Kim University of Ulsan, South Korea
Ragini Kudchadkar Emory University School of Medicine, Atlanta, GA, USA
James Larkin Royal Marsden Hospital, London, UK
Robert R McWilliams Mayo Clinic, Rochester, MN, USA
Sofia Merajver University of Michigan, Ann Arbour, MI, USA
Mark Middleton Oxford University, Oxford, UK
Nevin Murray British Columbia Cancer Agency, Canada
Paul Nathan Mount Vernon Cancer Centre, Northwood, UK
Sylvie Negrier Centre Léeon-Béerard, Lyon, France
Harvey I Pass New York University, New York, NY, USA
Edith A Perez Mayo Clinic, Jacsonville, FL, USA
Robert Pirker Medical University of Vienna, Vienna, Austria
Emilio Porfiri Birmingham University, Birmingham, UK
David Quinn University of Southern California, Los Angeles, CA, USA
Joseph D Rosenblatt University of Miami, Miami, FL, USA
Josep Tabernero Vall d'Hebron University Hospital, Barcelona, Spain
Scott T. Tagawa  
Toni Wozniak Wayne State University, Detroit, MI, USA
Andrew X Zhu Massachusetts General Hospital Cancer Center, Boston, MA, USA
  • Chemical Abstracts Service (CAS)
  • Medscape
  • PubMed Central
  • SCOPUS
  • Thomson Reuters: Science Citation Index Expanded
  • Please select a format:

    Individual, Single Print Issue

    £18.00
    $34.00

    Individual Subscription, Print Only

    £84.00
    $155.00

    Institutional, Single Print Issue

    £115.00
    $212.00

    Institutional Subscription, E-access

    £574.00
    $1,063.00

    Institutional Subscription, Print Only

    £625.00
    $1,157.00

    Institutional Subscription, Combined (Print & E-access)

    £638.00
    $1,181.00